Pearl Steinzor

The glucagon/GLP-1 dual agonist is noninferior to placebo for major adverse cardiovascular events and lowers blood pressure and waist size.

With the midterms behind them, health system leaders say coverage losses, thin margins, and payer fights are coming no matter who controls Congress.

In a matched analysis of Epic COSMOS records, acoramidis was tied to an 18% lower composite risk and about 25% lower hospitalization risk.

A runner's death at the NYC marathon highlights how heat, dehydration, illness, drugs, and genetics can raise exertional rhabdomyolysis risk.

The planned separation would keep Aetna, CVS Caremark, and Oak Street Health together and move roughly 9000 drugstores into a new CVS Pharmacy.

Many patients who stop a GLP-1 RA regain weight. How plans can measure adherence when cash-pay fills go unseen.

In more than 250,000 adults with prediabetes and obesity, GLP-1 users had lower risks of type 2 diabetes, death, and cardiovascular events.

In nearly 443,000 US adults, both low-frequency and heavy cannabis use were linked to higher odds of cardiovascular disease, led by stroke.

New abstracts show the oral PCSK9 inhibitor cut LDL-C by 57% to 63% across PREVENT risk groups, with reductions maintained in an extension study.

Patients on tegoprubart reported fewer transplant-related symptoms and better quality of life at 12 months than those on tacrolimus in phase 2 BESTOW.

Facing steep 2027 cost increases, employers are narrowing obesity drug coverage, while direct-to-employer models let them cap what they spend.

HHS enforcement discretion lets state pharmacies compound BPC-157 and other peptides amid rulemaking and legal challenges.

A clinical-note analysis of more than 1000 patients found rising off-label BPC-157 use for pain and healing, with outcomes unproven.

In TRANSCEND-T2D-2, retatrutide lowered A1C 2.2 points vs 1.8 with semaglutide 2 mg and more than doubled weight loss at 80 weeks.

Shields Health Solutions leaders say GLP-1 discontinuation is a support problem, not a medication problem, and pharmacist-led care can help close it.

Most Medicaid unwinding losses were procedural. mPulse's SriVani Ganti explains how plans can keep eligible members.

Insulin icodec-abae becomes the first once-weekly basal insulin cleared for children 10 years and older with type 2 diabetes.

Nearly 72% of patients hospitalized for heart failure had 2 or more other CKM conditions, with the strongest links to poor outcomes in HFrEF.

Among nearly 48 million US adults eligible for obesity medications, oral semaglutide initiation climbed quickly after its December 2025 FDA approval.

A 35-year Danish registry study found MACE declined in every income quartile, but the lowest earners kept higher rates than top earners throughout.

Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.

A retrospective study suggests strength exercise may be a safer option than endurance exercise for some people with ACM.

The pilot pairs grocery stipends and community health worker support with members who have unmanaged diabetes and unmet social needs.

Leon W. Herndon Jr, MD, explains how disease severity, medication adherence, and pressure spikes shape surgical planning.

David G. Mitchell, PharmD, MBA, CSP, FCPhA, of UC Davis Health, explains how AI-assisted prior authorizations have reduced denials and staff time without replacing pharmacist judgment.

Nearly half of working-age adults were inadequately insured in 2026, and half went without needed care due to cost, a Commonwealth Fund survey found.

Ambient AI and analytics may ease clinical workloads and uncover insights, but safety, validated data, HIPAA compliance, and equity must guide adoption.

Most specialty pharmacist interventions were routine refill and adherence touchpoints, with symptom trends driving higher-stakes provider escalations.

Tiara Green of Accessia Health says demand for charitable patient assistance is outpacing donations as inflation and Part D changes strain patients.

Nearly 3 in 4 bariatric surgery candidates had clinical obesity, a phenotype that BMI alone did not distinguish from preclinical obesity.